Tussigon

Acute Bronchitis, Pain, Chronic Pain + 10 more

Treatment

2 FDA approvals

10 Active Studies for Tussigon

What is Tussigon

Hydrocodone

The Generic name of this drug

Treatment Summary

Hydrocodone is an opioid medication used to treat moderate to severe pain. It is usually combined with acetaminophen for this purpose. In the past, hydrocodone was used as a cough suppressant, but it has mostly been replaced by a different drug called dextromethorphan. A more powerful form of hydrocodone, called hydromorphone, is used to treat severe pain. The FDA first approved hydrocodone in 1943 as part of a cough suppressant syrup called Hycodan.

Hycodan

is the brand name

image of different drug pills on a surface

Tussigon Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Hycodan

Hydrocodone

1943

1122

Approved as Treatment by the FDA

Hydrocodone, otherwise called Hycodan, is approved by the FDA for 2 uses including Pain and Pain .

Pain

Used to treat Severe Pain in combination with Acetaminophen

Pain

Helps manage moderate Pain

Effectiveness

How Tussigon Affects Patients

Hydrocodone is a drug that helps to block pain signals from reaching the brain and spinal cord. It can also cause a sense of pleasure, slower breathing, and drowsiness.

How Tussigon works in the body

Hydrocodone works by blocking pain signals in the spinal cord and brain. It binds to two different opioid receptors, the mu and delta receptors, with the mu receptor being most important for pain relief. Once bound, it prevents the release of neurotransmitters in the spinal cord and stops certain nerve cells from being activated. In the brain, it stops a GABAergic tone in the periaquaductal gray area, which suppresses pain signals. It can also activate reward and addiction pathways. Finally, it causes a decrease in activity of certain calcium channels, which contributes to pain relief and respiratory depression.

When to interrupt dosage

The prescribed dosage of Tussigon is contingent upon the identified condition, such as Coughing, Coughing and Chronic Pain. The measure of dosage varies as per the mode of administration (e.g. Tablet, extended release - Oral or Tablet - Oral) presented in the table beneath.

Condition

Dosage

Administration

Acute Bronchitis

7.5 mg, , 5.0 mg, 10.0 mg, 1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.75 mg/mL, 0.075 mg/mL, 2.5 mg, 10.0 mg/mL, 15.0 mg, 20.0 mg, 30.0 mg, 40.0 mg, 50.0 mg, 60.0 mg, 80.0 mg, 100.0 mg, 120.0 mg, 0.5 mg/mL, 90.0 mg, 750.0 mg, 45.0 mg, 3.0 mg/mL, 0.33 mg/mL, 1.65 mg/mL, 1.7 mg/mL, 1.667 mg/mL, 1.8 mg/mL, 1.67 mg/mL

, Tablet, film coated - Oral, Tablet, film coated, Oral, Syrup - Oral, Syrup, Capsule, extended release, Capsule, extended release - Oral, Solution - Oral, Solution, Tablet, Tablet - Oral, Suspension, extended release, Suspension, extended release - Oral, Tablet, coated, Tablet, coated - Oral, Kit, Tablet, extended release, Suspension, Suspension - Oral, Tablet, extended release - Oral, Liquid - Oral, Liquid, Topical, Cream - Topical, Cream, Elixir, Elixir - Oral, Capsule, Capsule - Oral

Pain

7.5 mg, , 5.0 mg, 10.0 mg, 1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.75 mg/mL, 0.075 mg/mL, 2.5 mg, 10.0 mg/mL, 15.0 mg, 20.0 mg, 30.0 mg, 40.0 mg, 50.0 mg, 60.0 mg, 80.0 mg, 100.0 mg, 120.0 mg, 0.5 mg/mL, 90.0 mg, 750.0 mg, 45.0 mg, 3.0 mg/mL, 0.33 mg/mL, 1.65 mg/mL, 1.7 mg/mL, 1.667 mg/mL, 1.8 mg/mL, 1.67 mg/mL

, Tablet, film coated - Oral, Tablet, film coated, Oral, Syrup - Oral, Syrup, Capsule, extended release, Capsule, extended release - Oral, Solution - Oral, Solution, Tablet, Tablet - Oral, Suspension, extended release, Suspension, extended release - Oral, Tablet, coated, Tablet, coated - Oral, Kit, Tablet, extended release, Suspension, Suspension - Oral, Tablet, extended release - Oral, Liquid - Oral, Liquid, Topical, Cream - Topical, Cream, Elixir, Elixir - Oral, Capsule, Capsule - Oral

Chronic Pain

7.5 mg, , 5.0 mg, 10.0 mg, 1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.75 mg/mL, 0.075 mg/mL, 2.5 mg, 10.0 mg/mL, 15.0 mg, 20.0 mg, 30.0 mg, 40.0 mg, 50.0 mg, 60.0 mg, 80.0 mg, 100.0 mg, 120.0 mg, 0.5 mg/mL, 90.0 mg, 750.0 mg, 45.0 mg, 3.0 mg/mL, 0.33 mg/mL, 1.65 mg/mL, 1.7 mg/mL, 1.667 mg/mL, 1.8 mg/mL, 1.67 mg/mL

, Tablet, film coated - Oral, Tablet, film coated, Oral, Syrup - Oral, Syrup, Capsule, extended release, Capsule, extended release - Oral, Solution - Oral, Solution, Tablet, Tablet - Oral, Suspension, extended release, Suspension, extended release - Oral, Tablet, coated, Tablet, coated - Oral, Kit, Tablet, extended release, Suspension, Suspension - Oral, Tablet, extended release - Oral, Liquid - Oral, Liquid, Topical, Cream - Topical, Cream, Elixir, Elixir - Oral, Capsule, Capsule - Oral

Inflammation

7.5 mg, , 5.0 mg, 10.0 mg, 1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.75 mg/mL, 0.075 mg/mL, 2.5 mg, 10.0 mg/mL, 15.0 mg, 20.0 mg, 30.0 mg, 40.0 mg, 50.0 mg, 60.0 mg, 80.0 mg, 100.0 mg, 120.0 mg, 0.5 mg/mL, 90.0 mg, 750.0 mg, 45.0 mg, 3.0 mg/mL, 0.33 mg/mL, 1.65 mg/mL, 1.7 mg/mL, 1.667 mg/mL, 1.8 mg/mL, 1.67 mg/mL

, Tablet, film coated - Oral, Tablet, film coated, Oral, Syrup - Oral, Syrup, Capsule, extended release, Capsule, extended release - Oral, Solution - Oral, Solution, Tablet, Tablet - Oral, Suspension, extended release, Suspension, extended release - Oral, Tablet, coated, Tablet, coated - Oral, Kit, Tablet, extended release, Suspension, Suspension - Oral, Tablet, extended release - Oral, Liquid - Oral, Liquid, Topical, Cream - Topical, Cream, Elixir, Elixir - Oral, Capsule, Capsule - Oral

Pain

7.5 mg, , 5.0 mg, 10.0 mg, 1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.75 mg/mL, 0.075 mg/mL, 2.5 mg, 10.0 mg/mL, 15.0 mg, 20.0 mg, 30.0 mg, 40.0 mg, 50.0 mg, 60.0 mg, 80.0 mg, 100.0 mg, 120.0 mg, 0.5 mg/mL, 90.0 mg, 750.0 mg, 45.0 mg, 3.0 mg/mL, 0.33 mg/mL, 1.65 mg/mL, 1.7 mg/mL, 1.667 mg/mL, 1.8 mg/mL, 1.67 mg/mL

, Tablet, film coated - Oral, Tablet, film coated, Oral, Syrup - Oral, Syrup, Capsule, extended release, Capsule, extended release - Oral, Solution - Oral, Solution, Tablet, Tablet - Oral, Suspension, extended release, Suspension, extended release - Oral, Tablet, coated, Tablet, coated - Oral, Kit, Tablet, extended release, Suspension, Suspension - Oral, Tablet, extended release - Oral, Liquid - Oral, Liquid, Topical, Cream - Topical, Cream, Elixir, Elixir - Oral, Capsule, Capsule - Oral

Acute Pain

7.5 mg, , 5.0 mg, 10.0 mg, 1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.75 mg/mL, 0.075 mg/mL, 2.5 mg, 10.0 mg/mL, 15.0 mg, 20.0 mg, 30.0 mg, 40.0 mg, 50.0 mg, 60.0 mg, 80.0 mg, 100.0 mg, 120.0 mg, 0.5 mg/mL, 90.0 mg, 750.0 mg, 45.0 mg, 3.0 mg/mL, 0.33 mg/mL, 1.65 mg/mL, 1.7 mg/mL, 1.667 mg/mL, 1.8 mg/mL, 1.67 mg/mL

, Tablet, film coated - Oral, Tablet, film coated, Oral, Syrup - Oral, Syrup, Capsule, extended release, Capsule, extended release - Oral, Solution - Oral, Solution, Tablet, Tablet - Oral, Suspension, extended release, Suspension, extended release - Oral, Tablet, coated, Tablet, coated - Oral, Kit, Tablet, extended release, Suspension, Suspension - Oral, Tablet, extended release - Oral, Liquid - Oral, Liquid, Topical, Cream - Topical, Cream, Elixir, Elixir - Oral, Capsule, Capsule - Oral

Rhinitis, Allergic

7.5 mg, , 5.0 mg, 10.0 mg, 1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.75 mg/mL, 0.075 mg/mL, 2.5 mg, 10.0 mg/mL, 15.0 mg, 20.0 mg, 30.0 mg, 40.0 mg, 50.0 mg, 60.0 mg, 80.0 mg, 100.0 mg, 120.0 mg, 0.5 mg/mL, 90.0 mg, 750.0 mg, 45.0 mg, 3.0 mg/mL, 0.33 mg/mL, 1.65 mg/mL, 1.7 mg/mL, 1.667 mg/mL, 1.8 mg/mL, 1.67 mg/mL

, Tablet, film coated - Oral, Tablet, film coated, Oral, Syrup - Oral, Syrup, Capsule, extended release, Capsule, extended release - Oral, Solution - Oral, Solution, Tablet, Tablet - Oral, Suspension, extended release, Suspension, extended release - Oral, Tablet, coated, Tablet, coated - Oral, Kit, Tablet, extended release, Suspension, Suspension - Oral, Tablet, extended release - Oral, Liquid - Oral, Liquid, Topical, Cream - Topical, Cream, Elixir, Elixir - Oral, Capsule, Capsule - Oral

Rhinitis

7.5 mg, , 5.0 mg, 10.0 mg, 1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.75 mg/mL, 0.075 mg/mL, 2.5 mg, 10.0 mg/mL, 15.0 mg, 20.0 mg, 30.0 mg, 40.0 mg, 50.0 mg, 60.0 mg, 80.0 mg, 100.0 mg, 120.0 mg, 0.5 mg/mL, 90.0 mg, 750.0 mg, 45.0 mg, 3.0 mg/mL, 0.33 mg/mL, 1.65 mg/mL, 1.7 mg/mL, 1.667 mg/mL, 1.8 mg/mL, 1.67 mg/mL

, Tablet, film coated - Oral, Tablet, film coated, Oral, Syrup - Oral, Syrup, Capsule, extended release, Capsule, extended release - Oral, Solution - Oral, Solution, Tablet, Tablet - Oral, Suspension, extended release, Suspension, extended release - Oral, Tablet, coated, Tablet, coated - Oral, Kit, Tablet, extended release, Suspension, Suspension - Oral, Tablet, extended release - Oral, Liquid - Oral, Liquid, Topical, Cream - Topical, Cream, Elixir, Elixir - Oral, Capsule, Capsule - Oral

Common Cold

7.5 mg, , 5.0 mg, 10.0 mg, 1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.75 mg/mL, 0.075 mg/mL, 2.5 mg, 10.0 mg/mL, 15.0 mg, 20.0 mg, 30.0 mg, 40.0 mg, 50.0 mg, 60.0 mg, 80.0 mg, 100.0 mg, 120.0 mg, 0.5 mg/mL, 90.0 mg, 750.0 mg, 45.0 mg, 3.0 mg/mL, 0.33 mg/mL, 1.65 mg/mL, 1.7 mg/mL, 1.667 mg/mL, 1.8 mg/mL, 1.67 mg/mL

, Tablet, film coated - Oral, Tablet, film coated, Oral, Syrup - Oral, Syrup, Capsule, extended release, Capsule, extended release - Oral, Solution - Oral, Solution, Tablet, Tablet - Oral, Suspension, extended release, Suspension, extended release - Oral, Tablet, coated, Tablet, coated - Oral, Kit, Tablet, extended release, Suspension, Suspension - Oral, Tablet, extended release - Oral, Liquid - Oral, Liquid, Topical, Cream - Topical, Cream, Elixir, Elixir - Oral, Capsule, Capsule - Oral

Allergic rhinitis (disorder)

7.5 mg, , 5.0 mg, 10.0 mg, 1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.75 mg/mL, 0.075 mg/mL, 2.5 mg, 10.0 mg/mL, 15.0 mg, 20.0 mg, 30.0 mg, 40.0 mg, 50.0 mg, 60.0 mg, 80.0 mg, 100.0 mg, 120.0 mg, 0.5 mg/mL, 90.0 mg, 750.0 mg, 45.0 mg, 3.0 mg/mL, 0.33 mg/mL, 1.65 mg/mL, 1.7 mg/mL, 1.667 mg/mL, 1.8 mg/mL, 1.67 mg/mL

, Tablet, film coated - Oral, Tablet, film coated, Oral, Syrup - Oral, Syrup, Capsule, extended release, Capsule, extended release - Oral, Solution - Oral, Solution, Tablet, Tablet - Oral, Suspension, extended release, Suspension, extended release - Oral, Tablet, coated, Tablet, coated - Oral, Kit, Tablet, extended release, Suspension, Suspension - Oral, Tablet, extended release - Oral, Liquid - Oral, Liquid, Topical, Cream - Topical, Cream, Elixir, Elixir - Oral, Capsule, Capsule - Oral

Coughing

7.5 mg, , 5.0 mg, 10.0 mg, 1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.75 mg/mL, 0.075 mg/mL, 2.5 mg, 10.0 mg/mL, 15.0 mg, 20.0 mg, 30.0 mg, 40.0 mg, 50.0 mg, 60.0 mg, 80.0 mg, 100.0 mg, 120.0 mg, 0.5 mg/mL, 90.0 mg, 750.0 mg, 45.0 mg, 3.0 mg/mL, 0.33 mg/mL, 1.65 mg/mL, 1.7 mg/mL, 1.667 mg/mL, 1.8 mg/mL, 1.67 mg/mL

, Tablet, film coated - Oral, Tablet, film coated, Oral, Syrup - Oral, Syrup, Capsule, extended release, Capsule, extended release - Oral, Solution - Oral, Solution, Tablet, Tablet - Oral, Suspension, extended release, Suspension, extended release - Oral, Tablet, coated, Tablet, coated - Oral, Kit, Tablet, extended release, Suspension, Suspension - Oral, Tablet, extended release - Oral, Liquid - Oral, Liquid, Topical, Cream - Topical, Cream, Elixir, Elixir - Oral, Capsule, Capsule - Oral

Common Cold

7.5 mg, , 5.0 mg, 10.0 mg, 1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.75 mg/mL, 0.075 mg/mL, 2.5 mg, 10.0 mg/mL, 15.0 mg, 20.0 mg, 30.0 mg, 40.0 mg, 50.0 mg, 60.0 mg, 80.0 mg, 100.0 mg, 120.0 mg, 0.5 mg/mL, 90.0 mg, 750.0 mg, 45.0 mg, 3.0 mg/mL, 0.33 mg/mL, 1.65 mg/mL, 1.7 mg/mL, 1.667 mg/mL, 1.8 mg/mL, 1.67 mg/mL

, Tablet, film coated - Oral, Tablet, film coated, Oral, Syrup - Oral, Syrup, Capsule, extended release, Capsule, extended release - Oral, Solution - Oral, Solution, Tablet, Tablet - Oral, Suspension, extended release, Suspension, extended release - Oral, Tablet, coated, Tablet, coated - Oral, Kit, Tablet, extended release, Suspension, Suspension - Oral, Tablet, extended release - Oral, Liquid - Oral, Liquid, Topical, Cream - Topical, Cream, Elixir, Elixir - Oral, Capsule, Capsule - Oral

Coughing

7.5 mg, , 5.0 mg, 10.0 mg, 1.0 mg/mL, 5.0 mg/mL, 2.5 mg/mL, 0.75 mg/mL, 0.075 mg/mL, 2.5 mg, 10.0 mg/mL, 15.0 mg, 20.0 mg, 30.0 mg, 40.0 mg, 50.0 mg, 60.0 mg, 80.0 mg, 100.0 mg, 120.0 mg, 0.5 mg/mL, 90.0 mg, 750.0 mg, 45.0 mg, 3.0 mg/mL, 0.33 mg/mL, 1.65 mg/mL, 1.7 mg/mL, 1.667 mg/mL, 1.8 mg/mL, 1.67 mg/mL

, Tablet, film coated - Oral, Tablet, film coated, Oral, Syrup - Oral, Syrup, Capsule, extended release, Capsule, extended release - Oral, Solution - Oral, Solution, Tablet, Tablet - Oral, Suspension, extended release, Suspension, extended release - Oral, Tablet, coated, Tablet, coated - Oral, Kit, Tablet, extended release, Suspension, Suspension - Oral, Tablet, extended release - Oral, Liquid - Oral, Liquid, Topical, Cream - Topical, Cream, Elixir, Elixir - Oral, Capsule, Capsule - Oral

Warnings

Tussigon has twenty-one recognized contraindications, and should not be administered alongside any of the conditions shown in the following table.

Tussigon Contraindications

Condition

Risk Level

Notes

Intestinal Pseudo-Obstruction

Do Not Combine

Asthma

Do Not Combine

Intracranial Hypertension

Do Not Combine

Status Asthmaticus

Do Not Combine

Asthma

Do Not Combine

increased cerebrospinal pressure

Do Not Combine

Mental Depression

Do Not Combine

Pulmonary Heart Disease

Do Not Combine

Abdomen

Do Not Combine

Epilepsy

Do Not Combine

Pulmonary Disease, Chronic Obstructive

Do Not Combine

ethanol

Do Not Combine

Gastrointestinal obstruction

Do Not Combine

Alcohol Withdrawal Delirium

Do Not Combine

Asthma

Do Not Combine

Hypercarbia

Do Not Combine

Asthma

Do Not Combine

severe CNS depression

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Hydrocodone may interact with Pulse Frequency

There are 20 known major drug interactions with Tussigon.

Common Tussigon Drug Interactions

Drug Name

Risk Level

Description

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Hydrocodone.

Azelastine

Major

Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Cyclophosphamide

Major

The metabolism of Cyclophosphamide can be decreased when combined with Hydrocodone.

Eluxadoline

Major

The risk or severity of constipation can be increased when Hydrocodone is combined with Eluxadoline.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Hydrocodone.

Tussigon Toxicity & Overdose Risk

Overdosing on hydrocodone can cause drowsiness, shallow breathing, cold and clammy skin, small pupils, fluid in the lungs, slow heartbeat, low blood pressure, and in extreme cases, death. To treat an overdose, it is important to keep the airway clear and provide assistance with breathing if necessary. Other treatments may involve IV fluids, oxygen, or medicines to increase blood pressure. In some cases, a medicine like naloxone can be used to reverse the effects of hydrocodone, but medical monitoring is still necessary as the effects may return. Naloxone can also cause withdrawal symptoms

Tussigon Novel Uses: Which Conditions Have a Clinical Trial Featuring Tussigon?

50 active clinical trials are currently examining the potential of Tussigon to alleviate Chronic Pain, Nasal Congestion caused by Common Cold and Acute Bronchitis.

Condition

Clinical Trials

Trial Phases

Acute Pain

1 Actively Recruiting

Not Applicable

Chronic Pain

0 Actively Recruiting

Pain

0 Actively Recruiting

Pain

0 Actively Recruiting

Rhinitis, Allergic

0 Actively Recruiting

Acute Bronchitis

7 Actively Recruiting

Phase 4, Not Applicable, Phase 3, Early Phase 1

Common Cold

0 Actively Recruiting

Allergic rhinitis (disorder)

0 Actively Recruiting

Rhinitis

0 Actively Recruiting

Inflammation

0 Actively Recruiting

Coughing

0 Actively Recruiting

Coughing

0 Actively Recruiting

Common Cold

0 Actively Recruiting

Tussigon Reviews: What are patients saying about Tussigon?

5

Patient Review

3/23/2009

Tussigon for Cough

This cough syrup is excellent. Not only does it work quickly, but it also tastes great and doesn't leave a nasty aftertaste. I would definitely recommend it to anyone looking for a good quality cough medicine.

5

Patient Review

1/20/2009

Tussigon for Cough

4.3

Patient Review

8/29/2014

Tussigon for Cough

This medicine is effective.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about tussigon

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can you get high on Tussigon?

"Tussigon contains hydrocodone, which is a substance that has a high potential for abuse and is similar to other opioids such as morphine and codeine."

Answered by AI

Is Tussigon an opioid?

"Tussigon is a prescription medication used to relieve dry coughs by containing two active drugs, hydrocodone and cough suppressant. Hydrocodone works to treat moderate to severe pain and, in Tussigon, stops the urge to cough."

Answered by AI

What is the drug Tussigon used for?

"Tussigon Tablets are a combination of a narcotic cough medicine and a medicine that works against the narcotic to prevent an overdose. They are used to treat cough."

Answered by AI

What is another name for Tussigon?

"Homatropine is an anticholinergic drug, typically used for short-term treatment."

Answered by AI

Clinical Trials for Tussigon

Image of AltaSciences, Inc in Cypress, United States.

SBS-147 Safety Study

18 - 55
All Sexes
Cypress, CA

This study is part of the HEAL Initiative supported by the NIH. The purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147. Some participants will receive SBS-147, and others will receive a placebo, which looks the same but does not contain any medicine. This helps researchers fairly compare results. The study includes two parts: Single-Dose Group, where Participants receive SBS-147 or placebo one time. Multiple-Dose Group, where Participants receive SBS-147 or placebo once or twice daily for 7 days.

Phase 1
Waitlist Available

AltaSciences, Inc

Jeff Reich, MD

Sparian Biosciences, Inc

Image of University of California San Diego in San Deigo, United States.

Omeprazole + Lifestyle Therapy for Laryngopharyngeal Reflux

18 - 89
All Sexes
San Deigo, CA

The goal of this clinical trial is to learn if a mechanism guided strategy that utilizes a multidisciplinary approach to treat adults patients (age 18-89) with chronic throat symptoms who are undergoing clinical evaluation for laryngopharyngeal reflux (LPR) is more effective than the usual care strategy with proton pump inhibitor (PPI) therapy used in gastroenterology for these patients. The main question it aims to answer is: Will a greater proportion of the mechanism guided strategy participants achieve symptom response in comparison to the usual care strategy participants? If there is a comparison group: Researchers will compare the mechanism guided strategy to usual care strategy to see if treatment response differs between the groups. Participants will be be asked to do the following: * participate in an 8-week blinded study phase where they will be randomized to either 1) Mechanism Guided Strategy or 2) Usual Care Strategy * take an oral capsule daily (omeprazole 40mg or placebo) * come to 3 in-person visits at UC San Diego Health for an intervention visit with a study provider * consider incorporating recommended lifestyle modifications * complete weekly surveys

Phase 4
Recruiting

University of California San Diego

Rena Yadlapati, MD

Image of Medical University of South Carolina in Charleston, United States.

Steroid Injection for Chronic Cough

18+
All Sexes
Charleston, SC

The primary goal of this study is to test the hypothesis that injecting steroid intramuscularly is an effective treatment for unexplained chronic cough. This will be achieved through the design of a prospective, placebo-controlled, single-blind, randomized clinical trial in which one group of patients will undergo a steroid injection into the deltoid muscle and the second group will undergo a placebo injection into the deltoid muscle. Data to determine if a clinically significant difference exists between the outcomes of the two groups will be measured by a dichotomous yes/no response to improvement, the Leicester Cough Questionnaire, and a visual analogue scale for symptom severity. This will provide the answer to the general question of whether or not the intramuscular injections are clinically effective for patients with unexplained chronic cough. Furthermore, any adverse reactions will be thoroughly documented. If this hypothesized treatment is proven effective, this can greatly improve the care of chronic cough patients by allowing for an evidence-based treatment option and a treatment option that may improve access to care. While the superior laryngeal nerve (SLN) injection is typically performed by fellowship trained laryngologists, intramuscular injections could be more widely utilized by general otolaryngologists or providers in other fields of medicine.

Phase < 1
Recruiting

Medical University of South Carolina

Lauren Howser

Have you considered Tussigon clinical trials?

We made a collection of clinical trials featuring Tussigon, we think they might fit your search criteria.
Go to Trials

Have you considered Tussigon clinical trials?

We made a collection of clinical trials featuring Tussigon, we think they might fit your search criteria.
Go to Trials